Clinical Trials Logo
  1. Home
  2. Extrahepatic Cholangiocarcinoma
  3. NCT02103179

VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC) — VEGF ECC  

Extrahepatic Cholangiocarcinoma Clinical Trial

Official title:
VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway

Clinical Trial Summary

The investigators study the VEGF signaling in ECC cell lines,patients and its mechanism in ECC growth, proliferation and apoptosis.

Clinical Trial Description

Several studies have documented the elevated expression of VEGF, VEGFR1 and VEGFR2 in cancer cell lines. Another study observed a sequential elevation of VEGF in low-grade dysplasia, high-grade dysplasia and early stage liver cancer. Clinical analyses have discovered the high expression of VEGF is correlated with tumor progression, vascular invasion, distal metastasis and poor prognosis. However, few studies have been conducted to investigate the VEGF signaling in ECC cells and its possible mechanism in regulating ECC growth.Therefore,we try to clarify the mechanism of VEGF signal in ECC growth,proliferation and apoptosis. ;

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02103179
Study type Observational
Source First Affiliated Hospital, Sun Yat-Sen University
Contact
Status Active, not recruiting
Phase N/A
Start date July 2006
Completion date September 2014
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05009953 - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Phase 2
Recruiting NCT06101277 - Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) N/A
Recruiting NCT05448183 - An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma Phase 2
Active, not recruiting NCT04333927 - Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer Phase 2
Recruiting NCT04561453 - Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
Not yet recruiting NCT06440993 - Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma Phase 2
Recruiting NCT05519319 - Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma N/A
Enrolling by invitation NCT05233293 - Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma N/A
Recruiting NCT05712356 - A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors Phase 2